A phase Ia/b trial of ARX788 combined with toripalimab for HER2-low advanced breast cancer (ABC) and other HER2-expressing solid tumors

被引：0
|
作者：
Shao, Xiying
Kuang, Ming
Chen, Zhanhong
Zheng, Yabing
Li, Guangliang
Shen, Xia-Bo
Huang, Ping
Cao, Wenming
Xu, Lixia
Wang, Xiaojia
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Breast Med Oncol, Hangzhou, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Hepatopancreatobiliary Surg, Guangzhou, Peoples R China
[3] Univ Chinese Acad Sci, Canc Hosp, Breast Canc Ctr, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[4] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China
[6] Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13159
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study: Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation
    Lu, J.
    Budd, G. T.
    Frentzas, S.
    Park, H.
    Shannon, C.
    Rugo, H. S.
    O'Shaughnessy, J.
    Demichele, A.
    Tolaney, S. M.
    Eek, R. W.
    McCartney, A.
    Cuff, K.
    Esserman, L.
    Alika, A.
    Xu, D.
    Li, M.
    Le, T.
    L'Heureux, D. Z.
    Yan, J.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S223 - S223
  • [2] ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Hu, Xichun
    Zhang, Qingyuan
    Wang, Leiping
    Zhang, Jian
    Ouyang, Quchang
    Wang, Xiaojia
    Li, Wei
    Xie, Weimin
    Tong, Zhongsheng
    Wang, Shusen
    Xu, Faliang
    Sun, Tao
    Liu, Wei
    Chen, Zhendong
    Wu, Jinsheng
    Wang, Ying
    Wang, Haixia
    Yan, Min
    Wang, Xinshuai
    Wang, Jingfen
    Cao, Feilin
    Du, Yingying
    Zhang, Yongqiang
    Chen, Lilin
    Lu, Ping
    Sun, Sanyuan
    Zhang, Ruiwen
    Zang, Aimin
    Nie, Xiuqing
    Lei, Yuan
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [3] Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer br
    Zhang, Jian
    Ji, Dongmei
    Shen, Weina
    Xiao, Qin
    Gu, Yajia
    'Shaughnessy, Joyce
    Hu, Xichun
    CLINICAL CANCER RESEARCH, 2022, 28 (19) : 4212 - 4221
  • [4] ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+advanced breast cancer (ABC)
    Hu, Xichun
    Wang, Leiping
    Zhang, Jian
    Zhang, Qingyuan
    Ouyang, Quchang
    Wang, Xiaojia
    Li, Wei
    Xie, Weimin
    Tong, Zhongsheng
    Xu, Faliang
    Liu, Wei
    Wang, Shushen
    Sun, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer
    Hu, Xichun
    Zhang, Jian
    Ji, Dongmei
    Xia, Gang
    Ji, Yanping
    Xiong, Gaozhun
    Liang, Xuejun
    CANCER RESEARCH, 2020, 80 (04)
  • [6] HER2-low expression in patients with advanced or metastatic solid tumors
    Uzunparmak, B.
    Haymaker, C.
    Masciari, S.
    Wang, L.
    Lin, H.
    Gorur, A.
    Kirby, B.
    Cimo, A. -m.
    Kennon, A.
    Ding, Q.
    Urschel, G.
    Yuan, Y.
    Feng, G.
    Rizvi, Y.
    Hussain, A.
    Zhu, C.
    Kim, P.
    Abbadessa, G.
    Subbiah, V.
    Yap, T. A.
    Rodon, J.
    Piha-Paul, S. A.
    Meric-Bernstam, F.
    Dumbrava, E. E.
    ANNALS OF ONCOLOGY, 2023, 34 (11) : 1035 - 1046
  • [7] HER2-low expression in patients with advanced or metastatic solid tumors
    Uzunparmak, Burak
    Haymaker, Cara
    Raso, Gabriela
    Zhu, Chen
    Masciari, Serena
    Wang, Lei
    Kirby, Bryce
    Lin, Heather
    Gorur, Aysegul
    Cimo, Ann-Marie
    Kennon, Amber
    Ding, Qingqing
    Palmieri, Andrea
    Urschel, Gabriele Elizabeth
    Yuan, Ying
    Feng, Guoxin
    Rizvi, Yasmeen
    Hussain, Aisha
    Subbiah, Vivek
    Yap, Timothy Anthony
    Rodon-Ahnert, Jordi
    Piha-Paul, Sarina Anne
    Hong, David S.
    Meric-Bernstam, Funda
    Dumbrava, Ecaterina E.
    CANCER RESEARCH, 2023, 83 (07)
  • [8] Phase I study of GQ1005, a new generation HER2-ADC, in patients with HER2-expressing and HER2 mutated advanced solid tumors
    Zhou, Caicun
    Yang, Bo
    Deng, Ting
    Wang, Biyun
    Zhang, Jian
    Sun, Yuping
    Wang, Linlin
    Yang, Hongwei
    Wang, Jingfen
    Li, Wei
    Song, Qi
    Yang, Yuchong
    CANCER RESEARCH, 2024, 84 (07)
  • [9] Bond oracle HER2 IHC assay for identifying low to intermediate HER2-expressing breast cancer
    Reid, Victoria Ann
    Schwartz, Mark W.
    Kumar, Sonia
    White, Yvonne Alexandra
    Mazanet, Rosemary
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] How I treat HER2-low advanced breast cancer
    Schlam, Ilana
    Tolaney, Sara M.
    Tarantino, Paolo
    BREAST, 2023, 67 : 116 - 123
12345